Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremie Calais

Showing results (41-50 of 207) with videos related to

Pageof 21
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 10, 2019
<sup>111</sup>In-Pentetreotide Scintigraphy Versus <sup>68</sup>Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor BurdenThomas A Hope, Jeremie Calais, Li Zhang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 3, 2018
Reply: Comparison of <sup>68</sup>Ga-PSMA-11 and <sup>18</sup>F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective Trial Is on Its WayJeremie Calais, Wolfgang Peter Fendler, Ken Herrmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 3, 2024
Dosimetry of [<sup>177</sup>Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and MetaanalysisZachary Ells, Tristan R Grogan, Johannes Czernin, et al.
Clinical Nuclear Medicine|May 15, 2020
PSMA Expression in the Neovasculature Associated With Rectal Adenocarcinoma: A Potential Stromal Target for Nuclear TheranosticsIda Sonni, Justin Caron, Amar U Kishan, et al.
Frontiers in Oncology|September 5, 2025
Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancerHimisha Beltran, Jeremie Calais, Louise Emmett, et al.
BMC Cancer|January 9, 2019
Randomized prospective phase III trial of <sup>68</sup>Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]Jeremie Calais, Johannes Czernin, Wolfgang P Fendler, et al.
BMC Cancer|January 23, 2019
Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]Jeremie Calais, Johannes Czernin, Wolfgang P Fendler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 15, 2023
PSMA-Negative Lesion Progression Under <sup>177</sup>Lu-PSMA Radioligand TherapyVishnu Murthy, Martin Allen-Auerbach, Richard Lam, et al.
Radiology. Imaging Cancer|June 18, 2026
Liver Background Uptake of Prostate-specific Membrane Antigen-targeted PET Radiotracers: A Systematic Review and Meta-AnalysisGary A Ulaner, Ashwin S Parihar, Jeremie Calais, et al.
Nature Reviews. Urology|November 14, 2024
Molecular imaging of renal cell carcinomas: ready for prime timeQianyun Wu, Hongda Shao, Wei Zhai, et al.
Pageof 21

Showing results (41-50 of 207) with videos related to

Sort By:
Pageof 21
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 10, 2019
<sup>111</sup>In-Pentetreotide Scintigraphy Versus <sup>68</sup>Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor BurdenThomas A Hope, Jeremie Calais, Li Zhang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 3, 2018
Reply: Comparison of <sup>68</sup>Ga-PSMA-11 and <sup>18</sup>F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective Trial Is on Its WayJeremie Calais, Wolfgang Peter Fendler, Ken Herrmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 3, 2024
Dosimetry of [<sup>177</sup>Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and MetaanalysisZachary Ells, Tristan R Grogan, Johannes Czernin, et al.
Clinical Nuclear Medicine|May 15, 2020
PSMA Expression in the Neovasculature Associated With Rectal Adenocarcinoma: A Potential Stromal Target for Nuclear TheranosticsIda Sonni, Justin Caron, Amar U Kishan, et al.
Frontiers in Oncology|September 5, 2025
Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancerHimisha Beltran, Jeremie Calais, Louise Emmett, et al.
BMC Cancer|January 9, 2019
Randomized prospective phase III trial of <sup>68</sup>Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]Jeremie Calais, Johannes Czernin, Wolfgang P Fendler, et al.
BMC Cancer|January 23, 2019
Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]Jeremie Calais, Johannes Czernin, Wolfgang P Fendler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 15, 2023
PSMA-Negative Lesion Progression Under <sup>177</sup>Lu-PSMA Radioligand TherapyVishnu Murthy, Martin Allen-Auerbach, Richard Lam, et al.
Radiology. Imaging Cancer|June 18, 2026
Liver Background Uptake of Prostate-specific Membrane Antigen-targeted PET Radiotracers: A Systematic Review and Meta-AnalysisGary A Ulaner, Ashwin S Parihar, Jeremie Calais, et al.
Nature Reviews. Urology|November 14, 2024
Molecular imaging of renal cell carcinomas: ready for prime timeQianyun Wu, Hongda Shao, Wei Zhai, et al.
Pageof 21